fda amgen - Search News

Amgen, Obesity and FDA

Bloomberg on MSN · 1d

Amgen Discloses FDA Paused Study of Early-Stage Obesity Drug

Amgen Inc. sees the potential for 2025 revenues to top Wall Street estimates thanks to growth in cholesterol and cancer drugs.

Hosted on MSN · 1d

Amgen shares sink despite quarterly beat, FDA places obesity drug on clinical hold

Nearly 30 years after Matt Damon and Ben Affleck’s breakthrough movie, “Good Will Hunting,” they are sharing the screen again in the new Netflix film “RIP,” which is inspired by true events.

Investor's Business Daily on MSN · 20h

Amgen Shrugs Off A Surprise Setback For One Of Its Obesity Drugs

Amgen stock rose early Wednesday, though the biotech behemoth said the FDA placed one of its obesity treatments on clinical hold.

1d

Amgen profits rise, next MariTide studies start by mid-year

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

With recent launches and more to come, Amgen's biosimilar business is trending up

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

Pipeline Problems Mar Amgen’s Q4 Beat

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

6h

Amgen Q4 Earnings: Good Quarter, Ok Guidance, But MariTide Concerns Me (Rating Downgrade)

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results